Samsung Bioepis will directly sell 3 of its biosimilars
By Nho, Byung Chul | translator Kim, Jung-Ju
24.02.14 05:50:34
가나다라
0
Ends domestic sales and marketing partnership agreement with Yuhan Corp
The biosimilars Etoloce, Remaloce, and Adalloce contribute to saving in health insurance finances
Company establishes a domestic sales team consisting of 20 employees
▲(From the left) Samsung Bioepis’s Etoloce (Enbrel biosimilar), Remaloce (Remicade biosimilar), and Adalloce (Humira biosimilar)
Samsung Bioepis is expected to strengthen its sales and marketing force and network and switch to direct domestic sales of its 3 self-developed biosimilars.
According to industry sources, Samsung Bioepis will directly sell 3 of its biosimilars for autoimmune diseases (TNF-alpha inhibitors) in the domestic market from next month (March).
The products Samsung Bioepis will directly sell in Korea include Etoloce (Enbrel biosimilar), Remaloce (Remicade biosimilar), and Adalloce (Humira biosimilar), which were previously sold by Yuhan Corp.
In October 2017, Samsung Bioepis switched its distributor for its Etoloce and Remaloce from MSD to Yuhan Corp.
Afte
Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)